Published in Drugs on January 01, 1996
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev (2012) 1.03
Oral vs inhaled asthma therapy. Pros, cons and combinations. Drugs (1996) 0.75
Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol (1938) 10.21
Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science (1983) 9.51
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet (1991) 2.27
Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis (1990) 2.23
Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci U S A (1983) 2.01
Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med (1994) 1.93
Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis (1982) 1.89
Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet (1991) 1.82
Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med (1994) 1.28
Biological profile of leukotrienes C4 and D4. Acta Physiol Scand (1980) 1.25
Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis (1992) 1.18
Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am Rev Respir Dis (1987) 1.16
Eicosanoids and lung inflammation. Am Rev Respir Dis (1987) 1.11
Production and antagonism of cutaneous vascular permeability in the guinea pig in response to histamine, leukotrienes and A23187. J Pharmacol Exp Ther (1984) 0.90
Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol (1992) 0.89
The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis (1993) 0.88
Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis (1990) 0.86
Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis (1993) 0.85
Inhalation challenge with sulfidopeptide leukotrienes in human subjects. Chest (1986) 0.84
The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J (1994) 0.83
Inhaled PAF stimulates leukotriene and thromboxane A2 production in humans. J Appl Physiol (1985) (1991) 0.81
Regulation of the receptor system for leukotriene B4 on human neutrophils. Ann N Y Acad Sci (1988) 0.81
Leukotrienes as a target in asthma therapy. Drugs (1994) 0.81
Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Respir Dis (1993) 0.80
An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobar airways. J Pharmacol Exp Ther (1990) 0.79
Update on exercise-induced asthma. Ann Allergy (1993) 0.78
Histamine and leukotriene C4 effects on in vitro ciliary beat frequency of human upper respiratory cilia. Eur Arch Otorhinolaryngol (1994) 0.76
Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther (1993) 0.75
Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest (1994) 0.75
Leukotriene activity modulation in asthma. Drugs (1997) 0.95